PLEKHA4 knockdown induces apoptosis in melanoma cells through the MAPK and &beta;‑catenin signaling pathways

Yue,Yuyang; An,Guangqi; Cao,Shuxia; Li,Xiangdan; Du,Liping; Xu,Dongyuan; Liu,Lan

doi:10.3892/mmr.2025.13464

PLEKHA4 knockdown induces apoptosis in melanoma cells through the MAPK and β‑catenin signaling pathways

Authors:
- Yuyang Yue
- Guangqi An
- Shuxia Cao
- Xiangdan Li
- Liping Du
- Dongyuan Xu
- Lan Liu
View Affiliations

Affiliations: Department of Pathology, Yanbian University Hospital, Yanji, Jilin 133000, P.R. China, Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Key Laboratory of Cellular Function and Pharmacology of Jilin Province, Medical College of Yanbian University, Yanji, Jilin 133002, P.R. China, Center of Morphological Experiment, Medical College of Yanbian University, Yanji, Jilin 133002, P.R. China
Published online on: February 18, 2025 https://doi.org/10.3892/mmr.2025.13464
Article Number: 99
Copyright: © Yue et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant melanoma (MM) is a highly aggressive subtype of skin cancer characterized by a poor prognosis, particularly in the advanced stages. Despite advancements in targeted therapy and immunotherapy, the survival rates for MM remain low, underscoring the need for new therapeutic targets. Pleckstrin homology domain‑containing family A member 4 (PLEKHA4), which has regulatory functions in pivotal cellular processes, has emerged as a potential target in melanoma. The present study aimed to investigate the role of PLEKHA4 in melanoma progression, focusing on its influence on the MAPK and Wnt/β‑catenin signaling pathways. Bioinformatics analysis revealed that PLEKHA4 was upregulated in melanoma tissues, whereas PLEKHA4 knockdown in melanoma cell lines (A375 and A2058) significantly inhibited cell proliferation and migration, enhanced apoptosis and inhibited tumor growth in vivo. Mechanistic studies demonstrated that PLEKHA4 may exert its effects by modulating the MAPK signaling pathway through interactions with key proteins, including ERK, JNK and MEK. Additionally, PLEKHA4 was shown to impact apoptosis by regulating caspase‑3, COX2 and p65. Additionally, β‑catenin nuclear translocation was affected via the Wnt pathway. Moreover, PLEKHA4 knockdown reduced cMyc ubiquitination, consequently promoting its degradation. The present findings suggested that PLEKHA4 could promote melanoma cell proliferation by regulating both the MAPK and Wnt/β‑catenin pathways, thereby proposing PLEKHA4 as a promising therapeutic target for MM. Further studies are warranted to elucidate the mechanisms underlying PLEKHA4‑mediated modulation of cMyc ubiquitination.

View Figures

View References

1	Sood S, Jayachandiran R and Pandey S: Current advancements and novel strategies in the treatment of metastatic melanoma. Integr Cancer Ther. 20:15347354219900782021. View Article : Google Scholar : PubMed/NCBI
2	Lee CS, Thomas CM and Ng KE: An overview of the changing landscape of treatment for advanced melanoma. Pharmacotherapy. 37:319–333. 2017. View Article : Google Scholar : PubMed/NCBI
3	Cancer Genome Atlas Network, . Genomic classification of cutaneous melanoma. Cell. 161:1681–1696. 2015. View Article : Google Scholar : PubMed/NCBI
4	Inamdar GS, Madhunapantula SV and Robertson GP: Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail. Biochem Pharmacol. 80:624–637. 2010. View Article : Google Scholar : PubMed/NCBI
5	Samatar AA and Poulikakos PI: Targeting RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug Discov. 13:928–942. 2014. View Article : Google Scholar : PubMed/NCBI
6	Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, Rusu A, Irimie A, Atanasov AG, Slaby O, et al: A comprehensive review on MAPK: A promising therapeutic target in cancer. Cancers (Basel). 11:16182019. View Article : Google Scholar : PubMed/NCBI
7	Zhan T, Rindtorff N and Boutros M: Wnt signaling in cancer. Oncogene. 36:1461–1473. 2017. View Article : Google Scholar : PubMed/NCBI
8	Zhang Y and Wang X: Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 13:1652020. View Article : Google Scholar : PubMed/NCBI
9	Gajos-Michniewicz A and Czyz M: WNT signaling in melanoma. Int J Mol Sci. 21:48522020. View Article : Google Scholar : PubMed/NCBI
10	Pawlikowski JS, McBryan T, van Tuyn J, Drotar ME, Hewitt RN, Maier AB, King A, Blyth K, Wu H and Adams PD: Wnt signaling potentiates nevogenesis. Proc Natl Acad Sci USA. 110:16009–16014. 2013. View Article : Google Scholar : PubMed/NCBI
11	Juan J, Muraguchi T, Iezza G, Sears RC and McMahon M: Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev. 28:561–575. 2014. View Article : Google Scholar : PubMed/NCBI
12	Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M and Bosenberg M: β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell. 20:741–754. 2011. View Article : Google Scholar : PubMed/NCBI
13	Sun Q, Lee W, Mohri Y, Takeo M, Lim CH, Xu X, Myung P, Atit RP, Taketo MM, Moubarak RS, et al: A novel mouse model demonstrates that oncogenic melanocyte stem cells engender melanoma resembling human disease. Nat Commun. 10:50232019. View Article : Google Scholar : PubMed/NCBI
14	Chien AJ, Haydu LE, Biechele TL, Kulikauskas RM, Rizos H, Kefford RF, Scolyer RA, Moon RT and Long GV: Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling. PLoS One. 9:e947482014. View Article : Google Scholar : PubMed/NCBI
15	Zhi W, Wang Y, Jiang C, Gong Y, Chen Q, Mao X, Deng W and Zhao S: PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma. Front Immunol. 14:11282442023. View Article : Google Scholar : PubMed/NCBI
16	Gao X, Liu Y, Hong S, Yang H, Guan B and Ma X: PLEKHA4 is associated with tumour microenvironment, stemness, proliferation and poor prognosis of gliomas. J Integr Neurosci. 22:1352023. View Article : Google Scholar : PubMed/NCBI
17	He Y, Zheng W, Huo Y, Sa L, Zhang H, He G and Shang P: PLEKHA4 promotes glioblastoma progression through apoptosis inhibition, tumor cell migration, and macrophage infiltration. Immunobiology. 228:1527462023. View Article : Google Scholar : PubMed/NCBI
18	Shami Shah A, Batrouni AG, Kim D, Punyala A, Cao W, Han C, Goldberg ML, Smolka MB and Baskin JM: PLEKHA4/kramer attenuates dishevelled ubiquitination to modulate Wnt and planar cell polarity signaling. Cell Rep. 27:2157–2170.e8. 2019. View Article : Google Scholar : PubMed/NCBI
19	Koelblinger P, Thuerigen O and Dummer R: Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 30:125–133. 2018. View Article : Google Scholar : PubMed/NCBI
20	Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D and Wang Y: Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 11:7234–7242. 2005. View Article : Google Scholar : PubMed/NCBI
21	Jalili A, Mertz KD, Romanov J, Wagner C, Kalthoff F, Stuetz A, Pathria G, Gschaider M, Stingl G and Wagner SN: NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo. PLoS One. 8:e690642013. View Article : Google Scholar : PubMed/NCBI
22	Llombart V and Mansour MR: Therapeutic targeting of ‘undruggable’ MYC. EBioMedicine. 75:1037562022. View Article : Google Scholar : PubMed/NCBI
23	Sun XX, Sears RC and Dai MS: Deubiquitinating c-Myc: USP36 steps up in the nucleolus. Cell Cycle. 14:3786–3793. 2015. View Article : Google Scholar : PubMed/NCBI
24	Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD and Hersey P: Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res. 13:4934–4942. 2007. View Article : Google Scholar : PubMed/NCBI
25	Wang J and Tai G: Role of C-Jun N-terminal kinase in hepatocellular carcinoma development. Target Oncol. 11:723–738. 2016. View Article : Google Scholar : PubMed/NCBI
26	Feng C, He K, Zhang C, Su S, Li B, Li Y, Duan CY, Chen S, Chen R, Liu Y, et al: JNK contributes to the tumorigenic potential of human cholangiocarcinoma cells through the mTOR pathway regulated GRP78 induction. PLoS One. 9:e903882014. View Article : Google Scholar : PubMed/NCBI
27	Lu Z and Xu S: ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life. 58:621–631. 2006. View Article : Google Scholar : PubMed/NCBI
28	Sugiura R, Satoh R and Takasaki T: ERK: A double-edged sword in cancer. ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells. 10:25092021. View Article : Google Scholar : PubMed/NCBI
29	Thamkachy R, Kumar R, Rajasekharan KN and Sengupta S: ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: Efficiency of DAT1 in Ras-Raf mutated cells. Mol Cancer. 15:222016. View Article : Google Scholar : PubMed/NCBI
30	Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, Konopleva M and Andreeff M: Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: Mechanisms and superior antileukemic efficacy. Cancer Cell. 32:748–760.e6. 2017. View Article : Google Scholar : PubMed/NCBI
31	Park BG, Yoo CI, Kim HT, Kwon CH and Kim YK: Role of mitogen-activated protein kinases in hydrogen peroxide-induced cell death in osteoblastic cells. Toxicology. 215:115–125. 2005. View Article : Google Scholar : PubMed/NCBI
32	Boutahar N, Reynaud E, Lassabliere F and Borg J: Timing differences of signaling response in neuron cultures activated by glutamate analogue or free radicals. Brain Res. 1191:20–29. 2008. View Article : Google Scholar : PubMed/NCBI
33	Gungor H, Ilhan N and Eroksuz H: The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer. Biomed Pharmacother. 102:221–229. 2018. View Article : Google Scholar : PubMed/NCBI
34	Spano D and Catara G: Targeting the ubiquitin-proteasome system and recent advances in cancer therapy. Cells. 13:292023. View Article : Google Scholar : PubMed/NCBI
35	Jiang M, Qi L, Li L and Li Y: The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer. Cell Death Discov. 6:1122020. View Article : Google Scholar : PubMed/NCBI
36	Sun SC: The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol. 17:545–558. 2017. View Article : Google Scholar : PubMed/NCBI
37	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
38	Nagendraprabhu P and Sudhandiran G: Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2. Invest New Drugs. 29:207–224. 2011. View Article : Google Scholar : PubMed/NCBI
39	Wang Q, Zhou Y, Rychahou P, Harris JW, Zaytseva YY, Liu J, Wang C, Weiss HL, Liu C, Lee EY and Evers BM: Deptor is a novel target of Wnt/β-Catenin/c-Myc and contributes to colorectal cancer cell growth. Cancer Res. 78:3163–3175. 2018. View Article : Google Scholar : PubMed/NCBI
40	Dang CV: MYC on the path to cancer. Cell. 149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
41	Tsai WB, Aiba I, Long Y, Lin HK, Feun L, Savaraj N and Kuo MT: Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res. 72:2622–2633. 2012. View Article : Google Scholar : PubMed/NCBI
42	Chen H, Liu H and Qing G: Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 3:52018. View Article : Google Scholar : PubMed/NCBI
43	Hann SR: Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Semin Cancer Biol. 16:288–302. 2006. View Article : Google Scholar : PubMed/NCBI
44	Akutsu M, Dikic I and Bremm A: Ubiquitin chain diversity at a glance. J Cell Sci. 129:875–880. 2016. View Article : Google Scholar : PubMed/NCBI
45	Swatek KN and Komander D: Ubiquitin modifications. Cell Res. 26:399–422. 2016. View Article : Google Scholar : PubMed/NCBI
46	Haglund K and Dikic I: Ubiquitylation and cell signaling. EMBO J. 24:3353–3359. 2005. View Article : Google Scholar : PubMed/NCBI
47	Trulsson F, Akimov V, Robu M, van Overbeek N, Berrocal DAP, Shah RG, Cox J, Shah GM, Blagoev B and Vertegaal ACO: Deubiquitinating enzymes and the proteasome regulate preferential sets of ubiquitin substrates. Nat Commun. 13:27362022. View Article : Google Scholar : PubMed/NCBI
48	Wang J, Zhou Q, Ding J, Yin T, Ye P and Zhang Y: The conceivable functions of protein ubiquitination and deubiquitination in reproduction. Front Physiol. 13:8862612022. View Article : Google Scholar : PubMed/NCBI
49	Mevissen TET and Komander D: Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem. 86:159–192. 2017. View Article : Google Scholar : PubMed/NCBI
50	Sun T, Liu Z and Yang Q: The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. 19:1462020. View Article : Google Scholar : PubMed/NCBI
51	Komander D and Rape M: The ubiquitin code. Annu Rev Biochem. 81:203–229. 2012. View Article : Google Scholar : PubMed/NCBI